Belize vs Lithuania: Share of the population living with HIV receiving antiretroviral therapy
Belize
49.6%
in 2024
Lithuania
51.9%
in 2024
Belize rank
127th
Lithuania rank
124th
Share of the population living with HIV receiving antiretroviral therapy over time
- Belize
- Lithuania
How they compare
Lithuania currently reports 51.9% against 49.6% in Belize, a difference of 2.3%.
The two have swapped places 2 times across 35 shared years of data; in 1990 it was Lithuania ahead.
Belize ranks 127th and Lithuania ranks 124th of 149 countries.
Belize has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Belize | Lithuania | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 0.0% | 0.0% | — |
| 2000s | 10.0% | 3.2% | 6.8% | Belize |
| 2010s | 34.9% | 21.6% | 13.3% | Belize |
| 2020s | 44.8% | 44.2% | 0.7% | Belize |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Belize or Lithuania?
- Lithuania, at 51.9% against 49.6% in Belize as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Belize and Lithuania?
- 2.3%, with Lithuania ahead.
- How many years of comparable data are there for Belize and Lithuania?
- 35 years are reported by both, from 1990 to 2024.
- How do Belize and Lithuania rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Belize ranks 127th and Lithuania ranks 124th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.